Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 21 August 2026 - 14:00

Orphan designation: human anti-promyostatin monoclonal antibody (apitegromab) Treatment of spinal muscular atrophy, 14/12/2018 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2115

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters